Gliomatosis cerebri: no evidence for a separate brain tumor entity

Clicks: 94
ID: 117643
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #388 of 438 articles by views in acta neuropathologica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 438 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Gliomatosis cerebri (GC) is presently considered a distinct astrocytic glioma entity according to the WHO classification for CNS tumors. It is characterized by widespread, typically bilateral infiltration of the brain involving three or more lobes. Genetic studies of GC have to date been restricted to the analysis of individual glioma-associated genes, which revealed mutations in the isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 (TP53) genes in subsets of patients. Here, we report on a genome-wide analysis of DNA methylation and copy number aberrations in 25 GC patients. Results were compared with those obtained for 105 patients with various types of conventional, i.e., non-GC gliomas including diffuse astrocytic gliomas, oligodendrogliomas and glioblastomas. In addition, we assessed the prognostic role of methylation profiles and recurrent DNA copy number aberrations in GC patients. Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups. Two tumors showed methylation profiles of normal brain tissue due to low tumor cell content. While histological grading (WHO grade IV vs. WHO grade II and III) was not prognostic, the molecular classification as classic/RTK2 or mesenchymal glioblastoma was associated with worse overall survival. Multivariate Cox regression analysis revealed MGMT promoter methylation as a positive prognostic factor. Taken together, DNA-based large-scale molecular profiling indicates that GC comprises a genetically and epigenetically heterogeneous group of diffuse gliomas that carry DNA methylation and copy number profiles closely matching the common molecularly defined glioma entities. These data support the removal of GC as a distinct glioma entity in the upcoming revision of the WHO classification.
Reference Key
herrlinger2015actagliomatosis Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ulrich Herrlinger;David T. W. Jones;Martin Glas;Elke Hattingen;Dorothee Gramatzki;Moritz Stuplich;Jörg Felsberg;Oliver Bähr;Gerrit H. Gielen;Matthias Simon;Dorothee Wiewrodt;Martin Schabet;Volker Hovestadt;David Capper;Joachim P. Steinbach;Andreas von Deimling;Peter Lichter;Stefan M. Pfister;Michael Weller;Guido Reifenberger;Ulrich Herrlinger;David T. W. Jones;Martin Glas;Elke Hattingen;Dorothee Gramatzki;Moritz Stuplich;Jörg Felsberg;Oliver Bähr;Gerrit H. Gielen;Matthias Simon;Dorothee Wiewrodt;Martin Schabet;Volker Hovestadt;David Capper;Joachim P. Steinbach;Andreas von Deimling;Peter Lichter;Stefan M. Pfister;Michael Weller;Guido Reifenberger;
Journal acta neuropathologica
Year 2015
DOI
doi:10.1007/s00401-015-1495-z
URL
https://link.springer.com/article/10.1007/s00401-015-1495-z
Keywords
pathology neurosciences

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.